Crispr-mediated epigenetic reactivation therapy for prader-willi syndrome
This innovative CRISPR-based therapy aims to reactivate silenced maternal genes in Prader-Willi Syndrome (PWS) by using dCas9 epigenome editors. The approach targets neuronal cells and has shown promising results in iPSCs, neurons, and mouse models.
Overview
Prader-Willi Syndrome (PWS) is a rare genetic disorder characterized by developmental and behavioral issues due to the loss of paternal gene expression on chromosome 15. This solution offers a novel CRISPR-mediated approach to reactivate silenced maternal PWS genes in neurons, the primary affected cell type. By employing dCas9-based epigenome editors, this therapy aims to restore normal gene function and ameliorate PWS-associated phenotypes, potentially offering a one-time gene therapy solution.
Technical specifications
This technology utilizes compact CRISPR/dCas9 variants, such as S. aureus and S. uberis, for targeted epigenetic editing. These variants, compatible with AAV delivery, enable the reactivation of the PWS locus by editing the chromatin landscape. Experiments have demonstrated success in human iPSCs and mouse models, with tools like dSpCas9-2xVP64 and TET1c showing stable reprogramming. The approach also involves comprehensive off-target analyses to ensure safety and specificity, with a focus on AAV9-mediated delivery for potential clinical applications.
Technology readiness level
Currently at Technology Readiness Level 3, this CRISPR-based therapy has been validated in laboratory settings using iPSCs and animal models. The next steps involve further validation and optimization for clinical applications, with ongoing research to assess the stability and safety of gene reactivation in vivo.
About Duke University
Duke University is a mid-sized, comprehensive private research university in Durham, North Carolina, anchored by a globally recognized academic medical center. Co-located campus and clinical facilities enable rapid bench-to-bedside translation, and shared core laboratories are accessible to external partners. Proximity to Research Triangle Park links Duke to a dense network of R&D-intensive companies, supported by centralized corporate engagement for sponsored research and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD. A dedicated technology transfer office supports IP strategy, licensing, startups, and industry collaboration.
Inquire about this partnering listing
Industry applications
delivered to your inbox.